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Abstract
Introduction Transanal total mesorectal excision
(TaTME) has rapidly emerged as a novel approach for
rectal cancer surgery. Safety profiles are still emerging
and more comparative data is urgently needed. This
study aimed to compare indications and short-term out-
comes of TaTME, open, laparoscopic, and robotic
TME internationally.
Methods A pre-planned analysis of the European Soci-
ety of Coloproctology (ESCP) 2017 audit was per-
formed. Patients undergoing elective total mesorectal
excision (TME) for malignancy between 1 January
2017 and 15 March 2017 by any operative approach
were included. The primary outcome measure was anas-
tomotic leak.
Results Of 2579 included patients, 76.2% (1966/2579)
underwent TME with restorative anastomosis of which
19.9% (312/1966) had a minimally invasive approach
(laparoscopic or robotic) which included a transanal com-
ponent (TaTME). Overall, 9.0% (175/1951, 15 missing
outcome data) of patients suffered an anastomotic leak.
On univariate analysis both laparoscopic TaTME (OR
1.61, 1.02–2.48, P = 0.04) and robotic TaTME (OR
3.05, 1.10–7.34, P = 0.02) were associated with a higher
risk of anastomotic leak than non-transanal laparoscopic
TME. However this association was lost in the mixed-
effects model controlling for patient and disease factors
(OR 1.23, 0.77–1.97, P = 0.39 and OR 2.11, 0.79–
5.62, P = 0.14 respectively), whilst low rectal anastomo-
sis (OR 2.72, 1.55–4.77, P < 0.001) and male gender
(OR 2.29, 1.52–3.44, P < 0.001) remained strongly
associated. The overall positive circumferential margin
resection rate was 4.0%, which varied between operative
approaches: laparoscopic 3.2%, transanal 3.8%, open
4.7%, robotic 1%.
Conclusion This contemporaneous international snap-
shot shows that uptake of the TaTME approach is
widespread and is associated with surgically and patho-
logically acceptable results.
Keywords Rectal cancer, laparoscopic surgery, TME,
transanal TME, TaTME, robotic surgery
What does this paper add to the literature?
Approaches to rectal cancer resection vary internation-
ally. One in five patients is undergoing a TaTME
approach, with results suggesting equivalent anasto-
motic leak and positive resection margin rates. Both
robotic and TaTME approaches need further evidence
to support their impact on major complications. Anas-
tomotic leak rates in low rectal anastomoses remain
high, regardless of operative approach.
Introduction
The best technique to achieve safe and effective total
mesorectal excision (TME) for rectal cancer continues
to pose a significant challenge for surgeons and patients.
The ideal technique aims for an intact TME with clear
circumferential and distal resection margins [1]. When
reconstruction is planned, an anastomotic technique
that minimises the risk of leak whilst promoting good
function is needed. A significant challenge is posed by
cancers in the lowest third of the rectum, particularly in
a narrow pelvis. From an abdominal approach, the abil-
ity to pass a stapler safely below the tumour is vital to
avoid an involved distal resection margin. Similarly, the
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need for multiple firings of a cross-stapler predisposes
to anastomotic leak [2]. Finally, precise placement of
circular stapling devices through cross-stapled rectal
stumps can be challenging.
Transanal TME (TaTME) has been proposed as a
method to improve surgery of mid and low rectal
lesions [3,4]. It is typically performed as a hybrid
procedure with a minimally invasive (laparoscopic or
robotic) abdominal approach, with dissection and
ultralow colorectal/coloanal anastomosis through the
transanal port to improve visualisation and avoid cross
stapling [5] or multiple firings [2,5]. It has the
potential to be safer for the distal resection margin by
improving access and precision of dissection and sta-
pler placement [2].
TaTME is still evolving (IDEAL Phase 2b) with
moderate stability of its components [6,7]. A pro-
longed learning curve [8] for transanal surgery has
been described, with worse outcomes seen in as many
as the first fifty cases performed [9]. Consistent with
this, early series report anastomotic leak rates as high
as 43% [10], with concerning rates of urethral and
other solid organ injury. Concerns also exist about
circumferential resection margin (CRM) involvement
and suboptimal TME specimen grades in its early
adoption [9,11]. There is not yet randomised evi-
dence for the benefit of TaTME. A recent large and
comprehensive registry study has identified baseline
data and showed acceptable leak rates and safety pro-
files from the included centres [12]. However, it did
not have comparative groups to benchmark current
practice, and so to supplement this, we planned a
study from a wide range of centres to gather compar-
ative data. The primary aim of this study was to
describe the safety profile of TaTME compared to
other surgical approaches to manage rectal cancer.
The secondary aim was to additionally describe the
current landscape in terms of uptake of TaTME and
the alternate operative approaches for rectal cancer,
including open, laparoscopic, and robotic TME.
Method
Protocol and centres
This prospective, observational, multicentre study was
conducted in line with a pre-specified protocol
(http://www.escp.eu.com/research/cohort-studies). An
external pilot of the protocol and data capture system
was conducted in five international centres prior to
launch, allowing refinement of the study tool and
delivery. Any unit performing gastrointestinal surgery
was eligible to register to enter patients into the
study. No minimum case volume, or centre-specific
limitations were applied. The study protocol was dis-
seminated to registered members European Society of
Coloproctology (ESCP), and through national surgical
or colorectal societies, and represents a pre-planned
analysis of the European Society of Coloproctology
2017 audit database.
Study approvals
All participating centres were responsible for compliance
to local approval requirements for ethics approval or
indemnity as required. In the UK, the National
Research Ethics Service tool recommended that this
project was not classified as research, and the protocol
was registered as clinical audit in all participating
centres.
Patient eligibility
Adult patients (> 16 years) undergoing elective
(planned) rectal resection with or without a primary
anastomosis were extracted from the main audit data-
base. Only operations performed for a malignant
pathology within the rectum, up to the rectosigmoid
junction were included. For the abdominal component,
open, laparoscopic and robotic procedures were all eligi-
ble. Transanal and non-transanal approaches were
acceptable. Rectal resections performed as part of a
more extensive resection (e.g. panproctocolectomy)
were excluded.
Data capture
Consecutive sampling was performed of eligible
patients over an 8-week study period in each included
centres. Local investigators commenced data collection
on any date between the 1 January 2017 and 15
March 2017, with the last eligible patient being
enrolled on 10 May 2017. This study adopted the
UK National Research Collaborative model for data
collection and follow-up. Small teams of up to five
surgeons or surgical trainees worked together to col-
lect prospective data on all eligible patients at each
centre. Quality assurance was provided by at least one
consultant or attending-level surgeon. Data was
recorded contemporaneously and stored on a secure,
user-encrypted online platform (REDCap) without
using patient identifiable information. Centres were
asked to validate that all eligible patients during
the study period had been entered, and to attain
> 95% completeness of data field entry prior to final
submission.
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Outcome measure
The primary outcome measure was overall anastomotic
leak, pre-defined as either (i) gross anastomotic leakage
proven radiologically or clinically, or (ii) the presence of
an intraperitoneal (abdominal or pelvic) fluid collection
on post-operative imaging. The secondary outcome
measures were the postoperative major complication
rate; defined as Clavien-Dindo classification grade 3–5
(reoperation, reintervention, unplanned admission to
critical care, organ support requirement or death), post-
operative length of stay (in whole days); with day of
surgery as day zero, the intraoperative serious adverse
event (SAE) rate, and the circumferential resection mar-
gin involvement rate; defined as tumour tissue ≤ 1 mm
from the resection margin.
Statistical analysis
This report has been prepared in accordance to guideli-
nes set by the STROBE (strengthening the reporting of
observational studies in epidemiology) statement for
observational studies [13]. Patient, disease and operative
characteristics were compared by type of surgical
approach (open, laparoscopic – transanal (TaTME),
laparoscopic – not transanal, robotic – transanal
(TaTME), robotic – not transanal) and by the presence
or absence of the primary outcome measure (anasto-
motic leak or intraperitoneal collection) using Student’s
t-test for normal, continuous data, Mann-Whitney U
test for non-normal continuous data or Chi-squared test
for categorical data. To test the association between
overall anastomotic leak and approach (the main
explanatory variable) two models were fitted: the first
was a mixed-effects logistic regression model using the
whole dataset, the second was a propensity score-
matched group of patients who did and did not
undergo TaTME in a 1:2 ratio. In the mixed-effects
model, clinically plausible patient, disease and opera-
tion-specific factors were entered into the model for
risk-adjustment, treated as fixed effects. These were
defined a priori within the study protocol, and included
irrespective of their significance on univariate analysis.
Hospital was entered into the model as a random-effect,
to adjust for hospital-level variation in outcome.
Propensity score matching was used to estimate the
effect of approach (transanal versus not transanal
perineal approach) by accounting for confounding
co-variables that might predict patient selection. Nearest
neighbour matching was used with scores calculated
from variables selected a priori for model adjustment
(age, gender, anastomotic height, AJCC stage), and
outputs were examined using jitter plots and Chi-
squared testing to observe any significant differences
between groups. A second propensity-score matched
multivariable logistic regression model was then fitted
to explore the association of operative approach and
anastomotic leak. Effect estimates are presented as odds
ratios (OR) with 95% confidence intervals (95% CI) and
two-tailed P-values. An alpha level of 0.05 was used
throughout. Model discrimination was tested by calcu-
lating a C-statistic (analogous to the area under the
Receiver Operating Curve (AUC); 0.5: no discrimina-
tion; 0.6, adequate; 0.7, good; 0.8 excellent). Multiple
imputation was not required as the data completeness
rate was very high for data points used for propensity
score matching. Data analysis was undertaken using R
Studio V3.1.1 (R Foundation, Boston, MA, USA).
Results
Patient demographics
Figure 1 shows inclusion of patients within this study.
A total of 2579 patients were included from 355 cen-
tres across 49 countries. The mean age of the cohort
was 66 years (18–98 years), of which 27.7% (715/
2579) had low, 26.0% (670/2579) had middle and
46.3% (1194/2579) had high rectal anastomoses.
62.7% were men (1617/2579) and 36.5% (942/2579)
underwent neoadjuvant therapy, of which 72.1% (679/
942) had long course chemoradiotherapy. A majority of
tumours were either T2 (21.8%, 563/2579) or T3
(51.8%, 1337/2579), N0 (58.4%, 1505/2579) and M0
(87.7%, 2262/2579). The abdominoperineal resection
rate was 15.4% (396/2579, Fig. 2) and resection with
end stoma formation was 8.4% (217/2579). Of those
that had an anastomosis (76.2%, 1966/2579), 92.1%
(1811/1966) had a stapled anastomosis.
Patient, disease and operative characteristics by
operative approach
There was variation in the selection of patients for
different approaches to rectal cancer surgery (Table 1).
Of patients undergoing restorative surgery, 15.9%
(312/1966) of patients from 189 centres underwent
surgery with a transanal perineal approach and mini-
mally invasive abdominal approach (TaTME), ranging
from one to 15 submitted cases per centre. 6.4%
(126/1966) of patients from 40 centres had robotic
surgery (ranging from one to 18 submitted case per
centre). In patients undergoing TaTME, the anasto-
mosis was was stapled in 73.7% (230/312) and hand-
sewn in 26.3% (82/312). The proportion of males
undergoing transanal and robotic approaches was
Colorectal Disease ª 2018 The Association of Coloproctology of Great Britain and Ireland. 20 (Suppl. 6), 33–46 35
The 2017 European Society of Coloproctology (ESCP) Collaborating Group Operative approach and postoperative outcome in rectal cancer surgery
slightly higher when compared to the other proce-
dures (68.4%, 68.3%, 64.4% vs 61.8%, 60.6% respec-
tively; P = 0.06). Transanal or robotic approaches
were significantly more likely to be selected in low
risk ASA 1-2 patients and earlier stage disease.
Anastomotic leak
Within the patients undergoing restorative anastomosis,
the overall leak rate was 9.0% (175/1951, with 15 miss-
ing outcome data (< 1%)). In the unadjusted data, the
Figure 1 Flowchart for patients included in the analysis of approaches to elective rectal cancer surgery.
Figure 2 Selection of approach by tumour height in elective rectal cancer surgery.
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Table 1 Patient, disease and operation characteristics by approach.
Factor Levels
Laparoscopic
not transanal
Laparoscopic
transanal Open
Robotic
not transanal
Robotic
transanal P-value
Operation type Primary
anastomosis
952 (81.0) 280 (76.3) 608 (70.0) 95 (77.2) 31 (68.9) < 0.001
ELAPE 35 (3.0) 25 (6.8) 46 (5.3) 6 (4.9) 1 (2.2)
APER 83 (7.1) 51 (13.9) 121 (13.9) 15 (12.2) 13 (28.9)
Hartmanns 106 (9.0) 11 (3.0) 93 (10.7) 7 (5.7) 0 (0.0)
Anastomosis height High rectum 398 (33.8) 46 (12.5) 195 (22.5) 18 (14.6) 1 (2.2) < 0.001
Mid rectum 336 (28.6) 66 (18.0) 227 (26.2) 30 (24.4) 3 (6.7)
Low rectum 318 (27.0) 171 (46.6) 280 (32.3) 51 (41.5) 24 (53.3)
APER 124 (10.5) 84 (22.9) 166 (19.1) 24 (19.5) 17 (37.8)
Patient characteristics
Age < 55 172 (14.6) 68 (18.5) 135 (15.6) 18 (14.6) 8 (17.8) 0.918
55–70 521 (44.3) 161 (43.9) 387 (44.6) 57 (46.3) 19 (42.2)
70–80 339 (28.8) 103 (28.1) 257 (29.6) 35 (28.5) 13 (28.9)
> 80 143 (12.2) 34 (9.3) 89 (10.3) 13 (10.6) 5 (11.1)
Missing 1 (0.1) 1 (0.3) 0 (0.0) 0 (0.0) 0 (0.0)
Gender Female 449 (38.2) 116 (31.6) 342 (39.4) 39 (31.7) 16 (35.6) 0.066
Male 727 (61.8) 251 (68.4) 526 (60.6) 84 (68.3) 29 (64.4)
ASA class Missing 20 (1.7) 2 (0.5) 4 (0.5) 0 (0.0) 0 (0.0) < 0.001
Low risk (ASA
1-2)
787 (66.9) 261 (71.1) 516 (59.4) 89 (72.4) 32 (71.1)
High risk (ASA
3-5)
369 (31.4) 104 (28.3) 348 (40.1) 34 (27.6) 13 (28.9)
BMI Normal weight 338 (28.7) 114 (31.1) 274 (31.6) 49 (39.8) 13 (28.9) 0.681
Underweight 23 (2.0) 9 (2.5) 21 (2.4) 2 (1.6) 0 (0.0)
Overweight 504 (42.9) 150 (40.9) 357 (41.1) 45 (36.6) 19 (42.2)
Obese 281 (23.9) 87 (23.7) 201 (23.2) 26 (21.1) 13 (28.9)
Missing 30 (2.6) 7 (1.9) 15 (1.7) 1 (0.8) 0 (0.0)
History of IHD/CVA Missing 2 (0.2) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0.041
No 998 (84.9) 325 (88.6) 704 (81.1) 103 (83.7) 41 (91.1)
Yes 176 (15.0) 42 (11.4) 164 (18.9) 20 (16.3) 4 (8.9)
History of
diabetes mellitus
Missing 3 (0.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0.35
No 995 (84.6) 302 (82.3) 736 (84.8) 111 (90.2) 36 (80.0)
Diabetes: any
control
178 (15.1) 65 (17.7) 132 (15.2) 12 (9.8) 9 (20.0)
Smoking history Non-smoker 997 (84.8) 300 (81.7) 723 (83.3) 107 (87.0) 40 (88.9) 0.122
Current 167 (14.2) 61 (16.6) 143 (16.5) 16 (13.0) 5 (11.1)
Missing 12 (1.0) 6 (1.6) 2 (0.2) 0 (0.0) 0 (0.0)
Disease characteristics
Neoadjuvant therapy Missing 9 (0.8) 2 (0.5) 15 (1.7) 0 (0.0) 0 (0.0) < 0.001
Chemotherapy
only
36 (3.1) 10 (2.7) 38 (4.4) 1 (0.8) 1 (2.2)
Long course
CRTx
266 (22.6) 142 (38.7) 215 (24.8) 32 (26.0) 24 (53.3)
Short course
radiotherapy
74 (6.3) 23 (6.3) 62 (7.1) 17 (13.8) 1 (2.2)
None 791 (67.3) 190 (51.8) 538 (62.0) 73 (59.3) 19 (42.2)
MRI T stage Missing 45 (3.8) 3 (0.8) 20 (2.3) 1 (0.8) 0 (0.0) < 0.001
T1 109 (9.3) 32 (8.7) 56 (6.5) 9 (7.3) 2 (4.4)
T2 242 (20.6) 68 (18.5) 196 (22.6) 44 (35.8) 13 (28.9)
T3 625 (53.1) 213 (58.0) 421 (48.5) 52 (42.3) 26 (57.8)
T4 155 (13.2) 51 (13.9) 175 (20.2) 17 (13.8) 4 (8.9)
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anastomotic leak rate was higher in TaTME (12.9%,
45/311, one missing outcome data (< 1%)) than non-
transanal TME (8.9%, 135/1520; Fig. 3). The highest
leak rate was seen in robotic surgery, and more major
complications were seen in transanal and robotic surgery
(Table 2). In the univariate analysis both laparoscopic
TaTME (OR 1.61, 1.02–2.48, P = 0.04) and robotic
TaTME (OR 3.05, 1.10–7.34, P = 0.02) were associ-
ated with a higher risk of anastomotic leak than non-
transanal laparoscopic TME. Once adjusted for con-
founders (Table 3, Fig. 4), transanal surgery was no
longer significantly associated with leak (OR 1.23,
0.77–1.97, P = 0.39 and OR 2.11, 0.79–5.62,
P = 0.14 respectively), whilst low rectal anastomosis
(OR 2.72, 1.55-4.77, P < 0.001) and male gender (OR
2.29, 1.52–3.44, P < 0.001) were strongly associated.
The model demonstrated fair discrimination (AUC:
0.70). Propensity score matching gave balanced groups
(Table 4). In the propensity matched multivariable
model (Table 5), transanal approach was not associated
with overall anastomotic leak (OR 1.14, 0.70–1.81,
P = 0.595). However, male gender (OR 2.88, 1.64–
5.38, P < 0.001) and low rectal anastomosis (OR 3.92,
1.74–10.52, P = 0.002) again remained strong predic-
tors for anastomotic leak.
Circumferential resection margin
In the unadjusted data, restorative surgery had a
lower CRM positivity rate (36/1733, with 232 miss-
ing outcome data (11.8%)) than non-restorative (58/
549) operations (2.3% versus 10.6%). Overall, there
was a low CRM positive rates across all approach
types to rectal resection with restorative anastomosis
(0–4.7%, Table 2). For the low rectum, robotic sur-
gery had a lower positive margin rate than laparo-
scopic surgery (0/19 with a transanal perineal
approach, and 1/27 with a non-transanal approach;
Table 1 (Continued).
Factor Levels
Laparoscopic
not transanal
Laparoscopic
transanal Open
Robotic
not transanal
Robotic
transanal P-value
MRI N stage Missing 38 (3.2) 3 (0.8) 17 (2.0) 1 (0.8) 0 (0.0) < 0.001
N0 699 (59.4) 248 (67.6) 443 (51.0) 79 (64.2) 36 (80.0)
N1 339 (28.8) 91 (24.8) 286 (32.9) 39 (31.7) 5 (11.1)
N2 100 (8.5) 25 (6.8) 122 (14.1) 4 (3.3) 4 (8.9)
MRI M stage Missing 30 (2.6) 3 (0.8) 17 (2.0) 0 (0.0) 0 (0.0) 0.239
M0 1022 (86.9) 326 (88.8) 759 (87.4) 112 (91.1) 43 (95.6)
M1 124 (10.5) 38 (10.4) 92 (10.6) 11 (8.9) 2 (4.4)
MRI AJCC stage Missing 46 (3.9) 4 (1.1) 18 (2.1) 0 (0.0) 0 (0.0) < 0.001
Stage 1 301 (25.6) 93 (25.3) 186 (21.4) 44 (35.8) 14 (31.1)
Stage 2 357 (30.4) 140 (38.1) 236 (27.2) 29 (23.6) 21 (46.7)
Stage 3 348 (29.6) 92 (25.1) 336 (38.7) 39 (31.7) 8 (17.8)
Stage 4 124 (10.5) 38 (10.4) 92 (10.6) 11 (8.9) 2 (4.4)
MRI EMVI Missing 127 (10.8) 42 (11.4) 80 (9.2) 7 (5.7) 4 (8.9) 0.366
No 954 (81.1) 295 (80.4) 721 (83.1) 111 (90.2) 36 (80.0)
Yes 95 (8.1) 30 (8.2) 67 (7.7) 5 (4.1) 5 (11.1)
MRI CRM Missing 136 (11.6) 44 (12.0) 88 (10.1) 7 (5.7) 5 (11.1) 0.353
No 909 (77.3) 289 (78.7) 674 (77.6) 106 (86.2) 36 (80.0)
Yes 131 (11.1) 34 (9.3) 106 (12.2) 10 (8.1) 4 (8.9)
Other operation characteristics
Anastomotic technique No anastomosis 224 (19.0) 87 (23.7) 260 (30.0) 28 (22.8) 14 (31.1) < 0.001
Handsewn 19 (1.6) 66 (18.0) 54 (6.2) 1 (0.8) 15 (33.3)
Stapled 933 (79.3) 214 (58.3) 554 (63.8) 94 (76.4) 16 (35.6)
Operator type Missing 1 (0.1) 2 (0.5) 0 (0.0) 0 (0.0) 0 (0.0) < 0.001
Colorectal 1010 (85.9) 333 (90.7) 704 (81.1) 105 (85.4) 38 (84.4)
General surgery 165 (14.0) 32 (8.7) 164 (18.9) 18 (14.6) 7 (15.6)
P-value derived from v2 test for categorical variables. % shown by column.
CRM, Circumferential resection margin (</> 1 mm); CVA, Cerebrovascular accident; EMVI, Extramural vascular invasion; IHD,
Ischemic heart disease; IQR, Interquartile range; MRI, Pre-neoadjuvant therapy, and/or baseline Magnetic Resonance Imaging
staging; N/A, Not applicable; SD, Standard deviation.
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Table 6). However, in a mixed-effects model
(Table 7), none of the operative approaches were sig-
nificantly associated with margin positivity except for
non-restorative surgery. The model demonstrated fair
discrimination (AUC: 0.72).
Discussion
This study supports the use of a TaTME approach for
rectal cancer resection, with comparable postoperative
outcomes and pathological safety compared to other
approaches. This is in line with recent evidence on
TaTME delivery across Europe [12,14,15]. The leak
rate was higher than previously reported, at 12.9%,
which at univariable level was significantly higher than
other techniques. Once adjusted for confounders, this
variability was largely a result of anastomosis in the low-
est part of the rectum; transanal surgery became non-
significant in mixed-effects and propensity-score
matched models. By including other techniques within
this study, it allows individual surgeons and units to
benchmark practice and consider their own selection of
patients. TaTME was more commonly used in men, in
those undergoing long course chemoradiotherapy and
in those with low tumours. This parallels current rec-
ommendations for the selection of patients, demonstrat-
ing appropriate adoption of this technique within
included centres [5,16].
Leak rates after transanal (TaTME) surgery have
been reported as 4.7% to 9.1% in recent systematic
reviews [5,11] and 6.7% in a subsequent large interna-
tional registry [17]. We add to this literature by provid-
ing an unselected, ‘real-world’ view of implementation
of TaTME internationally in a prospective setting, with
risk-adjustment of outcome data with mixed-effects
modelling. The higher unadjusted leak rate identified in
the present study may reflect learning curve effects from
centres being at variable stages of adoption of the tech-
nique. It may also reflect the fact that we only included
malignant conditions. An important variability between
studies still exists in how anastomotic leakage is defined
and detected. By comparing leakage to a simultaneous
Figure 3 Leak rates by approach and tumour height.
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cohort of laparoscopic, open and robotic resections
from the same centres, we can explore and control for
case selection variability by approach and mitigate
against concerns of reporting bias. Reassuringly, male
gender and low tumour height were strongly predictive
factors for leak in our mixed effects models, which is
consistent with current knowledge [18–20]. Whilst our
data gives evidence for safety in the current dissemina-
tion of TaTME, structured training with proctorship
from experienced proponents remains essential.
Improved pathological and oncological outcomes are
a potential benefit of TaTME. The positive resection
margin rate in restorative surgery from this study (4.0%)
is consistent with previous reports, including the transa-
nal component [5]. Fleshman et al. [21] previously
reported a significantly lower difference rate of CRM
involvement with TaTME when compared with laparo-
scopic TME. In contrast, the Bordeaux randomized trial
found a significantly greater rate of CRM involvement
for laparoscopic TME when compared to TaTME
(18.0% vs 4.0%, P = 0.025) although this did not mean
a decrease in local recurrence (long term oncological
outcomes) [22]. The low positive CRM rates seen with
robotic surgery in the lower rectum within the present
study are likely to represent a degree of case selection at
a site level; results from randomised trials in TaTME
and robotic rectal cancer surgery are awaited.
This study also provides valuable information for other
resection techniques. Recent randomised trials have sug-
gested laparoscopic TME may lack oncological safety
compared to open surgery in the mid and low rectum
(ALaCaRT and ACOSOG) [21,22]. The present study
shows pathological equivalence of laparoscopic and open
approaches, with a selection variability evident that sug-
gests surgeons are carefully and correctly selecting patients
for each approach; this is consistent with COLOR II,
COREAN and CLASiCC trials [18,19,23]. There were
relatively few robotic cases in this cohort. Where robotics
was performed, the positive CRM and conversion rates
were lower when compared to laparoscopic techniques.
The ROLARR trial with 471 patients did not show dif-
ferences between laparoscopic and robotic for positive
resection margin [24]. International registry studies
alongside ROLARR reported a rate of conversion from
laparoscopic to open or transanal of 6.3%. We found sig-
nificant differences between laparoscopic transanal that
presented the highest rate of conversion (16.2%) and
robotic transanal (0%). This is consistent with the findings
Table 2 Short-term intraoperative and postoperative outcomes by approach.
Factor Levels
Laparoscopic
not transanal
Laparoscopic
transanal Open
Robotic
not transanal
Robotic
transanal P-value
Postoperative outcomes
Anastomotic leak No leak 873 (74.2) 242 (65.9) 560 (64.5) 87 (70.7) 24 (53.3) < 0.001
Leak 79 (6.7) 38 (10.4) 48 (5.5) 8 (6.5) 7 (15.6)
No anastomosis 224 (19.0) 87 (23.7) 260 (30.0) 28 (22.8) 14 (31.1)
Complication grade Missing 6 (0.5) 1 (0.3) 4 (0.5) 2 (1.6) 2 (4.4) < 0.001
Grade 1-2 257 (21.9) 93 (25.3) 241 (27.8) 24 (19.5) 11 (24.4)
Grade 3-5 120 (10.2) 58 (15.8) 101 (11.6) 17 (13.8) 8 (17.8)
None 793 (67.4) 215 (58.6) 522 (60.1) 80 (65.0) 24 (53.3)
Pathological margin CRM involved 38 (3.2) 14 (3.8) 41 (4.7) 1 (0.8) 0 (0.0) 0.134
CRM not involved 1011 (86.0) 317 (86.4) 750 (86.4) 109 (88.6) 37 (82.2)
Missing 127 (10.8) 36 (9.8) 77 (8.9) 13 (10.6) 8 (17.8)
Length of stay Mean (SD) 8.4 (5.6) 10 (6.9) 10.7 (5.5) 7.7 (5.8) 9.9 (7.5) < 0.001
Intraoperative outcomes
Any intraoperative
complication
No 1124 (95.6) 354 (96.5) 834 (96.1) 120 (97.6) 38 (84.4) 0.003
Yes 52 (4.4) 13 (3.5) 34 (3.9) 3 (2.4) 7 (15.6)
Vascular injury No 1161 (98.7) 363 (98.9) 857 (98.7) 121 (98.4) 43 (95.6) 0.455
Yes 15 (1.3) 4 (1.1) 11 (1.3) 2 (1.6) 2 (4.4)
Bowel injury No 1163 (98.9) 365 (99.5) 858 (98.8) 121 (98.4) 42 (93.3) 0.01
Yes 13 (1.1) 2 (0.5) 10 (1.2) 2 (1.6) 3 (6.7)
Other organ injury No 1152 (98.0) 360 (98.1) 854 (98.4) 123 (100.0) 41 (91.1) 0.005
Yes 24 (2.0) 7 (1.9) 14 (1.6) 0 (0.0) 4 (8.9)
P-value derived from v2 test for categorical variables. % shown by column.
CRM, Circumferential resection margin (</> 1 mm); CVA, Cerebrovascular accident; IHD, Ischemic heart disease; IQR,
Interquartile range; N/A, Not applicable; SD, Standard deviation.
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Table 3 Univariable and multilevel models for overall anastomotic leak (primary outcome measure).
Factor Level
Anastomotic leak
OR (univariable) OR (multilevel)No leak Leak
Approach Laparoscopic
– not transanal
806 (48.1) 72 (44.2) – (Reference) – (Reference)
Laparoscopic
– transanal
223 (13.3) 32 (19.6) 1.61 (1.02–2.48, P = 0.036) 1.23 (0.77–1.97, P = 0.386)
Open 538 (32.1) 45 (27.6) 0.94 (0.63–1.37, P = 0.740) 0.93 (0.61–1.43, P = 0.745)
Robotic
– not transanal
86 (5.1) 8 (4.9) 1.04 (0.45–2.11, P = 0.917) 0.81 (0.36–1.78, P = 0.594)
Robotic
– transanal
22 (1.3) 6 (3.7) 3.05 (1.10–7.34, P = 0.019) 2.11 (0.79–5.62, P = 0.135)
Age < 55 278 (16.6) 29 (17.8) – –
55–70 775 (46.3) 77 (47.2) 0.95 (0.61–1.51, P = 0.831) 0.92 (0.58–1.47, P = 0.729)
70–80 481 (28.7) 47 (28.8) 0.94 (0.58–1.54, P = 0.792) 0.87 (0.51–1.48, P = 0.606)
> 80 141 (8.4) 10 (6.1) 0.68 (0.31–1.39, P = 0.311) 0.70 (0.31–1.58, P = 0.394)
Gender Female 629 (37.6) 34 (20.9) – –
Male 1046 (62.4) 129 (79.1) 2.28 (1.56–3.42, P < 0.001) 2.29 (1.52–3.44, P < 0.001)
ASA class Low risk (ASA 1-2) 1150 (68.7) 114 (69.9) – –
High risk (ASA 3-5) 525 (31.3) 49 (30.1) 0.94 (0.66–1.33, P = 0.736) 0.99 (0.66–1.49, P = 0.969)
BMI Normal weight 515 (30.7) 53 (32.5) – –
Underweight 30 (1.8) 4 (2.5) 1.30 (0.37–3.44, P = 0.639) 1.35 (0.45–4.10, P = 0.594)
Overweight 741 (44.2) 71 (43.6) 0.93 (0.64–1.36, P = 0.707) 0.89 (0.60–1.33, P = 0.577)
Obese 389 (23.2) 35 (21.5) 0.87 (0.56–1.36, P = 0.556) 0.86 (0.53–1.39, P = 0.534)
History of
IHD/CVA
No 1420 (84.8) 138 (84.7) – –
Yes 255 (15.2) 25 (15.3) 1.01 (0.63–1.55, P = 0.969) 1.16 (0.70–1.94, P = 0.567)
History of
diabetes mellitus
No 1431 (85.4) 140 (85.9) – –
Diabetes:
any control
244 (14.6) 23 (14.1) 0.96 (0.59–1.50, P = 0.874) 0.87 (0.53–1.42, P = 0.584)
Smoking history Non-smoker 1436 (85.7) 129 (79.1) – –
Current 239 (14.3) 34 (20.9) 1.58 (1.05–2.34, P = 0.025) 1.46 (0.95–2.23, P = 0.082)
Operator type Colorectal 1403 (83.8) 137 (84.0) – –
General surgery 272 (16.2) 26 (16.0) 0.98 (0.62–1.49, P = 0.924) 1.11 (0.68–1.81, P = 0.687)
Neoadjuvant
therapy
Chemotherapy only 69 (4.1) 3 (1.8) – –
Long course CRTx 368 (22.0) 48 (29.4) 3.00 (1.06–12.58, P = 0.071) 1.75 (0.51–5.99, P = 0.371)
Short course
radiotherapy
80 (4.8) 14 (8.6) 4.02 (1.25–17.98, P = 0.034) 2.74 (0.73–10.30, P = 0.136)
None 1158 (69.1) 98 (60.1) 1.95 (0.71–8.05, P = 0.266) 1.97 (0.59–6.55, P = 0.271)
Anastomosis
height
High rectum 525 (31.3) 29 (17.8) – –
Mid rectum 528 (31.5) 40 (24.5) 1.37 (0.84–2.26, P = 0.209) 1.33 (0.79–2.23, P = 0.277)
Low rectum 622 (37.1) 94 (57.7) 2.74 (1.80–4.28, P < 0.001) 2.72 (1.55–4.77, P < 0.001)
Anastomotic
configuration
End to End 1271 (75.9) 123 (75.5) – –
Side to Side 83 (5.0) 2 (1.2) 0.25 (0.04–0.80, P = 0.054) 0.27 (0.06–1.16, P = 0.079)
Side to End 321 (19.2) 38 (23.3) 1.22 (0.82–1.78, P = 0.303) 1.10 (0.73–1.65, P = 0.662)
Leak test
performed
No 543 (32.4) 54 (33.1) – –
Yes 1132 (67.6) 109 (66.9) 0.97 (0.69–1.37, P = 0.853) 1.11 (0.76–1.64, P = 0.584)
Defunctioning
stoma
Yes 720 (43.0) 93 (57.1) – –
No 955 (57.0) 70 (42.9) 0.57 (0.41–0.78, P = 0.001) 1.05 (0.68–1.63, P = 0.813)
AUROC:0.70, AIC: 1088.1
Overall anastomotic leak was pre-defined as either (i) gross anastomotic leakage proven radiologically or clinically, or (ii) the presence
of an intraperitoneal (abdominal or pelvic) fluid collection on post-operative imaging. Patients with missing outcome or risk adjustment
data have been excluded from this model. Odds ratio (OR) presented with 95% confidence intervals. % shown by column.
CRTx, Chemoradiotherapy; CVA, Cerebrovascular accident; IHD, Ischemic heart disease; IQR, Interquartile range; N/A, Not
applicable; SD, Standard deviation.
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Figure 4 Forest plot for mixed effects model of factors associated with anastomotic leak in elective rectal cancer surgery with
restorative anastomosis
Table 4 Balanced characteristics of propensity score matched groups.
Factor Level
Perineal approach
P-valueNot transanal Transanal
Age < 55 108 (20.1) 56 (20.9) 0.979
55–70 246 (45.9) 125 (46.6)
70–80 146 (27.2) 70 (26.1)
> 80 36 (6.7) 17 (6.3)
Gender Female 179 (33.4) 90 (33.6) 0.958
Male 357 (66.6) 178 (66.4)
Anastomosis height High rectum 100 (18.7) 46 (17.2) 0.041
Mid rectum 168 (31.3) 64 (23.9)
Low rectum 268 (50.0) 158 (59.0)
MRI AJCC stage Stage 1 167 (31.2) 72 (26.9) 0.553
Stage 2 177 (33.0) 100 (37.3)
Stage 3 138 (25.7) 68 (25.4)
Stage 4 54 (10.1) 28 (10.4)
P-value derived from v2 test for categorical variables. % shown by column.
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of ROLARR trial about the potential for robotic surgery
to decrease the rate of conversion.
Finally the APER rate provides a contemporary per-
manent stoma rate across a variety of international sites
for an operation with known variability between units
[25]. Our group plans to produce a future report
describing geographic variability in colorectal surgery,
exploring differences in patient factors, disease presenta-
tions and techniques utilised internationally, across the
last three international ESCP audits.
This study has limitations. Unadjusted outcomes
showed higher major complication rates with robotic
surgery and also transanal surgery, although without
risk adjustment for confounding factors this must be
interpreted with significant caution. Further research is
needed to correctly risk-adjust for individual surgeon,
or surgical team experience in TaTME, as well as
unmeasured patient, tumour and operation-specific fac-
tors. Similarly, standardised definitions of anastomotic
leakage and its detection remain uncommonly used
between studies. Selection bias is an unavoidable factor
in this type of observational research. We have
attempted to minimize the effects of this by undertak-
ing adjusted analyses using mixed-effects logistic regres-
sion models, but accept that this can never fully
counteract the nuances involved in clinical decision-
making. This said, the current study was designed to
detect safety differences in current practice rather than
test efficacy of treatments directly.
Results from randomised trials comparing outcomes
after the variety of approaches available for rectal cancer
surgery are now needed, particularly evaluating TaTME
against laparoscopic TME without a transanal perineal
component [26].
Table 5 Summary of propensity score matched multivariable model for overall anastomotic leak.
Factor Level OR (multivariable)
Transanal component No –
Yes 1.22 (0.75-1.96, P = 0.420)
Age < 55 –
55–70 0.92 (0.50-1.73, P = 0.777)
70–80 0.68 (0.34-1.39, P = 0.282)
> 80 0.47 (0.10-1.52, P = 0.253)
Gender Female –
Male 2.94 (1.65-5.60, P < 0.001)
Anastomosis height High rectum –
Mid rectum 1.81 (0.72-5.16, P = 0.23)
Low rectum 3.75 (1.66-10.10, P = 0.003)
MRI AJCC stage Stage 1 –
Stage 2 1.18 (0.64-2.25, P = 0.60)
Stage 3 1.55 (0.79-3.05, P = 0.203)
Stage 4 1.03 (0.40-2.47, P = 0.944)
Overall anastomotic leak was pre-defined as either (i) gross anastomotic leakage proven radiologically or clinically, or (ii) the pres-
ence of an intraperitoneal (abdominal or pelvic) fluid collection on post-operative imaging. Odds ratio (OR) presented with 95%
confidence intervals.
Table 6 Circumferential resection margin positive rates (pathological) by approach and height in rectum.
Open
Laparoscopic Robotic
Transanal Not transanal Transanal Not transanal
Low rectum
19/236 9/163 16/198 0/19 1/27
8.05% 5.52% 8.08% 0.00% 3.70%
Middle rectum
12/218 5/88 10/267 0/12 0/33
5.50% 5.68% 3.75% 0.00% 0.00%
High Rectum
10/337 0/80 12/584 0/6 0/50
2.96% 0.00% 2.05% 0.00% 0.00%
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Table 7 Univariable and multilevel models for circumferential resection margin involvement.
Factor Level
Resection margin
OR (univariable) OR (multilevel)Negative Positive
Transanal
component
No 1709 (79.3) 69 (76.7) – –
Yes 445 (20.7) 21 (23.3) 1.17 (0.69–1.89, P = 0.540) 0.96 (0.56–1.65, P = 0.889)
Approach Laparoscopic 1088 (50.5) 40 (44.4) – –
Open 934 (43.4) 49 (54.4) 1.43 (0.93–2.20, P = 0.102) 1.50 (0.93–2.42, P = 0.097)
Robotic 132 (6.1) 1 (1.1) 0.21 (0.01–0.96, P = 0.120) 0.17 (0.02–1.28, P = 0.086)
Age < 55 335 (15.6) 19 (21.1) – –
55–70 959 (44.5) 32 (35.6) 0.59 (0.33–1.07, P = 0.074) 0.57 (0.31–1.05, P = 0.072)
70–80 626 (29.1) 25 (27.8) 0.70 (0.38–1.31, P = 0.261) 0.75 (0.39–1.45, P = 0.393)
> 80 234 (10.9) 14 (15.6) 1.05 (0.51–2.14, P = 0.883) 1.37 (0.62–3.05, P = 0.440)
Gender Female 781 (36.3) 32 (35.6) – –
Male 1373 (63.7) 58 (64.4) 1.03 (0.67–1.62, P = 0.892) 1.08 (0.68–1.73, P = 0.733)
ASA class Low risk (ASA 1-2) 1426 (66.2) 63 (70.0) – –
High risk (ASA 3-5) 728 (33.8) 27 (30.0) 0.84 (0.52–1.31, P = 0.456) 0.64 (0.37–1.12, P = 0.116)
BMI Normal weight 672 (31.2) 25 (27.8) – –
Underweight 40 (1.9) 6 (6.7) 4.03 (1.43–9.82, P = 0.004) 4.71 (1.74–12.79, P = 0.002)
Overweight 929 (43.1) 39 (43.3) 1.13 (0.68–1.90, P = 0.644) 1.32 (0.77–2.26, P = 0.313)
Obese 513 (23.8) 20 (22.2) 1.05 (0.57–1.90, P = 0.878) 1.17 (0.62–2.23, P = 0.626)
History of
IHD/CVA
No 1797 (83.4) 72 (80.0) – –
Yes 357 (16.6) 18 (20.0) 1.26 (0.72–2.09, P = 0.394) 1.75 (0.93–3.26, P = 0.081)
History of
diabetes mellitus
No 1818 (84.4) 80 (88.9) – –
Diabetes:
any control
336 (15.6) 10 (11.1) 0.68 (0.33–1.26, P = 0.251) 0.62 (0.31–1.25, P = 0.180)
Smoking history Non-smoker 1824 (84.7) 74 (82.2) – –
Current 330 (15.3) 16 (17.8) 1.20 (0.66–2.02, P = 0.528) 1.10 (0.61–2.00, P = 0.756)
Operator type Colorectal 1836 (85.2) 79 (87.8) – –
General surgery 318 (14.8) 11 (12.2) 0.80 (0.40–1.46, P = 0.505) 0.91 (0.45–1.85, P = 0.791)
Neoadjuvant
therapy
Chemotherapy only 75 (3.5) 2 (2.2) – –
Long course CRTx 555 (25.8) 40 (44.4) 2.70 (0.81–16.81, P = 0.176) 2.17 (0.49–9.60, P = 0.307)
Short course
radiotherapy
156 (7.2) 9 (10.0) 2.16 (0.54–14.42, P = 0.331) 1.76 (0.35–8.76, P = 0.491)
None 1368 (63.5) 39 (43.3) 1.07 (0.32–6.65, P = 0.928) 1.11 (0.25–4.84, P = 0.891)
Anastomosis
height
High rectum 540 (25.1) 13 (14.4) – –
Mid rectum 574 (26.6) 16 (17.8) 1.16 (0.55–2.47, P = 0.698) 1.09 (0.51–2.31, P = 0.831)
Low rectum 714 (33.1) 24 (26.7) 1.40 (0.72–2.85, P = 0.339) 1.08 (0.50–2.30, P = 0.849)
APER 326 (15.1) 37 (41.1) 4.71 (2.53–9.33, P < 0.001) 3.55 (1.68–7.52, P = 0.001)
AUC:0.77, AIC: 731.5
Overall anastomotic leak was pre-defined as either (i) gross anastomotic leakage proven radiologically or clinically, or (ii) the pres-
ence of an intraperitoneal (abdominal or pelvic) fluid collection on post-operative imaging. Odds ratio (OR) presented with 95%
confidence intervals. % shown by column.
CRTx, Chemoradiotherapy; CVA, Cerebrovascular accident; IHD, Ischemic heart disease; IQR, Interquartile range; N/A, Not
applicable; SD, Standard deviation.
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